Literature DB >> 15925111

Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome.

Alberto C S Costa1, Michael J Grybko.   

Abstract

Down syndrome (DS) is the most common genetically defined cause of intellectual disabilities. Both hippocampal function and volume seem to be disproportionally reduced in individuals with DS and in at least one aneuploid murine model of DS, the Ts65Dn mouse. Two previous studies by one research group have reported deficits in long-term potentiation (LTP) induced by in vitro high-frequency stimulation (HFS) of hippocampal CA1 synapses of adult Ts65Dn mice. Here, we report on the results of our own investigation on LTP in Ts65Dn mice. This study was designed to confirm the previous findings and possibly shed some light onto potential mechanisms underlying the reported deficit in this important form of long-term synaptic plasticity in a mouse model of DS. LTP was induced in area CA1 with either theta burst stimulation (TBS) or HFS. Contrary to the previous reports, our results showed no significant difference in HFS-induced LTP between Ts65Dn and euploid littermate mice. We have found, however, a significant reduction of the amount of TBS-induced LTP in Ts65Dn mice compared to euploid controls. Because this specific LTP deficit can be rescued by bath application of picrotoxin (10 microM), we hypothesize that an increase in GABA(A)-mediated inhibition or in plasticity of the inhibitory circuitry in Ts65Dn mice may underlie the observed deficits. However, future experiments to examine the state of hippocampus CA1 GABAergic inhibition in Ts65Dn mice will be necessary to further explore these hypotheses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15925111     DOI: 10.1016/j.neulet.2005.03.031

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  80 in total

1.  Trisomy of the G protein-coupled K+ channel gene, Kcnj6, affects reward mechanisms, cognitive functions, and synaptic plasticity in mice.

Authors:  Ayelet Cooper; Gayane Grigoryan; Liora Guy-David; Michael M Tsoory; Alon Chen; Eitan Reuveny
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

2.  OLIG2 Drives Abnormal Neurodevelopmental Phenotypes in Human iPSC-Based Organoid and Chimeric Mouse Models of Down Syndrome.

Authors:  Ranjie Xu; Andrew T Brawner; Shenglan Li; Jing-Jing Liu; Hyosung Kim; Haipeng Xue; Zhiping P Pang; Woo-Yang Kim; Ronald P Hart; Ying Liu; Peng Jiang
Journal:  Cell Stem Cell       Date:  2019-05-23       Impact factor: 24.633

3.  Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome.

Authors:  Alexander M Kleschevnikov; Pavel V Belichenko; Jessica Gall; Lizzy George; Rachel Nosheny; Michael T Maloney; Ahmad Salehi; William C Mobley
Journal:  Neurobiol Dis       Date:  2011-10-17       Impact factor: 5.996

4.  Decreasing the Expression of GABAA α5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome.

Authors:  Verónica Vidal; Susana García-Cerro; Paula Martínez; Andrea Corrales; Sara Lantigua; Rebeca Vidal; Noemí Rueda; Laurence Ozmen; Maria-Clemencia Hernández; Carmen Martínez-Cué
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

5.  The Down syndrome critical region regulates retinogeniculate refinement.

Authors:  Martina Blank; Peter G Fuerst; Beth Stevens; Navid Nouri; Lowry Kirkby; Deepti Warrier; Ben A Barres; Marla B Feller; Andrew D Huberman; Robert W Burgess; Craig C Garner
Journal:  J Neurosci       Date:  2011-04-13       Impact factor: 6.167

Review 6.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

7.  Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model.

Authors:  Ishita Das; Joo-Min Park; Jung H Shin; Soo Kyeong Jeon; Hernan Lorenzi; David J Linden; Paul F Worley; Roger H Reeves
Journal:  Sci Transl Med       Date:  2013-09-04       Impact factor: 17.956

Review 8.  Molecular basis of pharmacotherapies for cognition in Down syndrome.

Authors:  Katheleen J Gardiner
Journal:  Trends Pharmacol Sci       Date:  2009-12-04       Impact factor: 14.819

9.  Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome.

Authors:  D Colas; B Chuluun; D Warrier; M Blank; D Z Wetmore; P Buckmaster; C C Garner; H C Heller
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

10.  A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome.

Authors:  Patricia Lopes Pereira; Laetitia Magnol; Ignasi Sahún; Véronique Brault; Arnaud Duchon; Paola Prandini; Agnès Gruart; Jean-Charles Bizot; Bernadette Chadefaux-Vekemans; Samuel Deutsch; Fabrice Trovero; José María Delgado-García; Stylianos E Antonarakis; Mara Dierssen; Yann Herault
Journal:  Hum Mol Genet       Date:  2009-09-26       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.